ME1 Inhibitors
ME1 inhibitors, as a chemical class, consist of compounds that indirectly affect the activity of Malic Enzyme 1 (ME1) by modulating various metabolic pathways and cellular processes. ME1 plays a pivotal role in metabolic flux, particularly in the conversion of malate to pyruvate while producing NADPH, which is crucial for redox balance and biosynthetic reactions. The primary action of these inhibitors is not direct inhibition of ME1 but rather an alteration of the metabolic environment in which ME1 operates, leading to a reduction in its activity or the flux through the pathway involving ME1. Compounds like Metformin, Phenformin, and Berberine function by activating AMPK, a key regulator of cellular energy homeostasis. AMPK activation leads to a shift in cellular metabolic states, which can result in a reduction of the metabolic flux through pathways that involve ME1. This reduction is due to the altered demand or availability of substrates and intermediates in the pathways where ME1 is active. Similarly, AICAR, through its AMPK activating properties, contributes to this modulation of metabolic pathways.
On the other hand, compounds like 2-Deoxy-D-glucose (2-DG), 3-Bromopyruvate, and Lonidamine target glycolysis, a major metabolic pathway. By inhibiting glycolysis, these compounds cause a shift in cellular metabolism away from glycolytic pathways, which can indirectly reduce ME1 activity. This reduction is a consequence of altered metabolic demands and the availability of substrates that are crucial for the function of ME1. Dichloroacetate (DCA), through activation of PDH, also shifts metabolism towards oxidative phosphorylation, thereby reducing the reliance on ME1 for NADPH production. Furthermore, compounds like Resveratrol, Rosiglitazone, Atorvastatin, and Rapamycin modulate different aspects of cellular metabolism, including lipid metabolism, glucose homeostasis, and cellular growth pathways. Their action results in an indirect modulation of ME1 activity.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Metformin | 657-24-9 | sc-507370 | 10 mg | $77.00 | 2 | |
Metformin, primarily known as an antidiabetic drug, can influence cellular metabolism, particularly by activating AMP-activated protein kinase (AMPK). Activation of AMPK can lead to altered metabolic fluxes that indirectly reduce ME1 activity, as AMPK modulates various enzymes in metabolic pathways. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
2-DG is a glucose analog that inhibits glycolysis. By inhibiting glycolysis, 2-DG can shift cellular metabolic pathways away from those involving ME1, potentially reducing ME1 activity indirectly due to altered substrate availability and metabolic demands. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $60.00 $270.00 $350.00 | 48 | |
AICAR activates AMPK, which in turn can modulate various metabolic pathways. Through its effect on AMPK, AICAR can indirectly influence ME1 activity by altering the cellular metabolic state, potentially reducing the flux through ME1-involved pathways. | ||||||
Dichloroacetic acid | 79-43-6 | sc-214877 sc-214877A | 25 g 100 g | $60.00 $125.00 | 5 | |
DCA activates pyruvate dehydrogenase (PDH), shifting metabolism from glycolysis to oxidative phosphorylation. This shift can indirectly reduce ME1 activity by altering the balance of metabolic intermediates and reducing reliance on ME1 for NADPH production. | ||||||
Lonidamine | 50264-69-2 | sc-203115 sc-203115A | 5 mg 25 mg | $103.00 $357.00 | 7 | |
Lonidamine inhibits hexokinase, a key enzyme in glycolysis. By inhibiting glycolysis, Lonidamine can indirectly reduce ME1 activity, as metabolic fluxes are shifted away from pathways involving ME1. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol, a natural polyphenol, is known to activate SIRT1, which in turn can influence cellular metabolism. Through its action on SIRT1 and related metabolic pathways, Resveratrol can indirectly modulate ME1 activity. | ||||||
Berberine | 2086-83-1 | sc-507337 | 250 mg | $90.00 | 1 | |
Berberine activates AMPK, leading to altered metabolic states. This activation can result in reduced ME1 activity by changing the flux through various metabolic pathways, including those involving ME1. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $118.00 $320.00 $622.00 $928.00 $1234.00 | 38 | |
Rosiglitazone, a PPAR-γ agonist, modulates lipid metabolism and glucose homeostasis. Through its effects on PPAR-γ, Rosiglitazone can indirectly influence ME1 activity by altering metabolic pathways that interact with or support ME1 function. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $252.00 $495.00 | 9 | |
Atorvastatin, a statin used for lowering cholesterol, can influence various aspects of cellular metabolism. Its effect on metabolic pathways can lead to an indirect reduction in ME1 activity by altering substrate availability and energy balance within the cell. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, alters cellular growth and metabolism. By inhibiting mTOR, Rapamycin can change the cellular metabolic profile, potentially reducing ME1 activity by influencing pathways that feed into or regulate ME1. | ||||||